Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73
First Affiliated Hospital of Fujian Medical University
30 participants
Mar 1, 2025
INTERVENTIONAL
Conditions
Summary
As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.
Eligibility
Inclusion Criteria1
- Signed informed consent and be able to follow up.
Exclusion Criteria1
- Pregnant or lactational women; who suffered from severe hepatic and renal insufficiency.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intravenous injection of 68Ga-dPNE. 68Ga-dPNE PET/CT will be used to detect tumors.
Intravenous injection of 18F-FDG.18F-FDG PET/CT will be used to detect tumors.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06995976